Metavention, Inc.

Metavention, Inc. is a Minneapolis-based biotechnology and health care company founded in 2012. The company's focus on developing innovative treatments for metabolic diseases has garnered significant attention from investors. In the most recent funding round in January 2018, Metavention received a substantial $65.00M Series C investment from a group of prominent backers including New Enterprise Associates, Versant Ventures, Sanderling Ventures, Horowitz Group, and RK Mellon. The company has a compelling vision encapsulated in their slogan, "Together, we can effect real change in the treatment of metabolic disease." This ethos drives their commitment to addressing the unmet needs in the treatment of metabolic disorders. With a strong and diverse backing from renowned venture capital firms, Metavention is well-positioned to continue its pioneering work in the field of metabolic disease management.